ACELYRIN
SLRN
SLRN was delisted on the 21st of May, 2025.
122 hedge funds and large institutions have $430M invested in ACELYRIN in 2024 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 44 increasing their positions, 35 reducing their positions, and 12 closing their positions.
83% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 12
26% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 35
12% more capital invested
Capital invested by funds: $384M → $430M (+$46.4M)
8% more funds holding
Funds holding: 113 → 122 (+9)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.46% less ownership
Funds ownership: 87.87% → 87.41% (-0.46%)
43% less call options, than puts
Call options by funds: $154K | Put options by funds: $272K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$36.6M |
| 2 |
SC
Stempoint Capital
New York
|
+$6.8M |
| 3 |
Millennium Management
New York
|
+$4.36M |
| 4 |
BlackRock
New York
|
+$3.68M |
| 5 |
Morgan Stanley
New York
|
+$2.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$23.7M |
| 2 |
JP Morgan Chase
New York
|
-$9.02M |
| 3 |
AG
Artal Group
Luxembourg
|
-$8.91M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$8.4M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$4.58M |
SLRN Hedge Fund Activity: Q3 2024 in Review
122 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in ACELYRIN (SLRN) for Q3 2024, worth a combined $430M — up 12% from $384M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new SLRN positions and 12 closed out — a net gain of 10 holders — while 44 added to existing stakes and 35 trimmed.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $36.6M. The largest seller was Fidelity Investments, cutting an estimated $23.7M.
- 122 institutional investors held ACELYRIN (SLRN) as of Q3 2024, up from 113 in Q2 2024.
- Funds reported $430M of ACELYRIN stock for Q3 2024, up 12% quarter-over-quarter.
- 22 funds opened new ACELYRIN positions in Q3 2024 and 12 closed out, a net change of +10 holders.
- The largest ACELYRIN buyer in Q3 2024 was T. Rowe Price Investment Management, an estimated $36.6M added.
- The largest ACELYRIN seller in Q3 2024 was Fidelity Investments, an estimated $23.7M sold.
Based on aggregated 13F filings for Q3 2024.